{"id":"W2950848761","doi":"10.1016/j.joco.2019.05.002","title":"Ocular adverse events with immune checkpoint inhibitors","year":2019,"lang":"en","type":"article","venue":"Journal of Current Ophthalmology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":99,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia","funders":"Foundation for Anesthesia Education and Research","keywords":"Medicine; Nivolumab; Pembrolizumab; Adverse effect; Ipilimumab; Atezolizumab; Uveitis; Durvalumab; Odds ratio; Adverse Event Reporting System; Internal medicine; Immunology; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000427097,0.0001560575,0.0004715378,0.0001962587,0.0000241146,0.000002752801,0.0001224451,0.00008327614,0.0009538633],"category_scores_gemma":[0.00002384068,0.0001029383,0.0003315565,0.0001806371,0.00006674435,0.0001104371,0.00002633212,0.0003914659,0.00005061645],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001266734,"about_ca_system_score_gemma":0.0002497947,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000006203792,"about_ca_topic_score_gemma":1.183862e-7,"domain_scores_codex":[0.9986033,0.00006308503,0.0006219101,0.0001364881,0.0003509225,0.0002242831],"domain_scores_gemma":[0.99889,0.0000290687,0.0005581893,0.0002170185,0.0001976793,0.0001080359],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.02515552,0.001751356,0.8122464,0.0005129924,0.001574367,0.002112343,0.0005020726,0.00005703789,0.1446932,0.00004766537,0.0006157411,0.01073133],"study_design_scores_gemma":[0.02691992,0.01345319,0.7843004,0.002520347,0.000504416,0.09777795,0.000497825,0.00003066772,0.0328542,0.000189013,0.0404302,0.0005218154],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9913278,0.004946927,0.00002777273,0.0004196528,0.00226297,0.000240321,0.000001633819,0.000005880229,0.0007670386],"genre_scores_gemma":[0.998911,0.0001663498,0.0002044698,0.00003567934,0.0002648491,0.000002289297,0.000003970814,0.00001889657,0.0003925514],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.111839,"threshold_uncertainty_score":0.9999594,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02193169367885373,"score_gpt":0.3123402495225097,"score_spread":0.2904085558436559,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}